

Preliminary Amendment

Q68625

4. A drug for treating or preventing progress of symptoms, through inhibiting cell death, of myasthenia gravis, comprising a indolylmaleimide derivative represented by the above formula (I) of Claim 1 or a pharmaceutically acceptable salt thereof as an active ingredient.

5. A drug for treating or preventing progress of symptoms, through inhibiting death of neurons, of brain ischemia and delayed neuronal death (DND), comprising a indolylmaleimide derivative represented by the above formula (I) of Claim 1 or a pharmaceutically acceptable salt thereof as an active ingredient.

6. A drug for treating or preventing progress of symptoms, through inhibiting death of myocardial cells, of ischemic heart disease, viral myocarditis, autoimmune myocarditis, myocardial disorders/cell death due to hypertrophic heart and heart failure, or arrhythmogenic right ventricular cardiomyopathy, comprising a indolylmaleimide derivative represented by the above formula (I) of Claim 1 or a pharmaceutically acceptable salt thereof as an active ingredient.

7. A drug for treating or preventing progress of symptoms, through inhibiting death of hepatic cells, of alcoholic hepatitis or viral hepatitis, comprising a indolylmaleimide derivative represented by the above formula (I) of Claim 1 or a pharmaceutically acceptable salt thereof as an active ingredient.

8. A drug for treating or preventing progress of symptoms, though inhibiting death of renal cells, or renal diseases, comprising a indolylmaleimide derivative represented by the above formula (I) of Claim 1 or a pharmaceutically acceptable salt thereof as an active ingredient.

Preliminary Amendment

Q68625

9. A drug for treating or preventing progress of symptoms, through inhibiting excessive death of T-cells, of acquired immunodeficiency syndrome (AIDS), comprising a indolylmaleimide derivative represented by the above formula (I) of Claim 1 or a pharmaceutically acceptable salt thereof as an active ingredient.

10. A drug for treating or preventing progress of symptoms, through inhibiting cell death, of inflammatory skin disorders, alopecia, or graft versus host disease (GVH), comprising a indolylmaleimide derivative represented by the above formula (I) of Claim 1 or a pharmaceutically acceptable salt thereof as an active ingredient.

11. A drug for treating or preventing disorders or side effects, through inhibiting cell death, of disorders due to radiation or drugs, comprising a indolylmaleimide derivative represented by the above formula (I) of Claim 1 or a pharmaceutically acceptable salt thereof as an active ingrdient.

12. A drug for treating or preventing progress of symptoms, through inhibiting cell death, of sepsis, comprising a indolylmaleimide derivative represented by the above formula (I) of Claim 1 or a pharmaceutically acceptable salt thereof as an active ingredient.

13. A drug for treating or preventing progress of symptoms, through inhibiting death of cells derived from bone marrow, of steomyelo-dysplasia, comprising a indolylmaleimide derivative represented by the above formula (I) of Claim 1 or a pharmaceutically acceptable salt thereof as an active ingredient.

14. A drug for treating or preventing progress of symptoms, through inhibiting cell death, of insulin dependent diabetes, comprising a indolylmaleimide derivative represented by the above formula (II) of Claim 1 or a pharmaceutically acceptable salt thereof as an active ingredient.

Preliminary Amendment

Q68625

15. A drug for treating or preventing progress of symptoms, through inhibiting death of neurons, of prion diseases, comprising a indolylmaleimide derivative represented by the above formula (I) of Claim 1 or a pharmaceutically acceptable salt thereof as an active ingredient.

16. A drug for treating or preventing functional deficiency of transplanted organs, tissues or cells at transplantation of organs, tissues or cells, comprising a indolylmaleimide derivative represented by the above formula (I) of Claim 1 or a pharmaceutically acceptable salt thereof as an active ingredient.

17. A preservative for organs, tissues or cells, comprising a indolylmaleimide derivative represented by the above formula (I) of Claim 1 or a pharmaceutically acceptable salt thereof as an active ingredient.

---

REMARKS

Claims 2-17 have been amended to make them dependent on Claim 1.

Entry and consideration of this Amendment is respectfully requested.

Respectfully submitted,

*John Callehan Reg. No. 32,607*  
for Mark Boland  
Registration No. 32,197

SUGHRUE MION, PLLC  
2100 Pennsylvania Avenue, N.W.  
Washington, D.C. 20037-3213  
Telephone: (202) 293-7060  
Facsimile: (202) 293-7860  
MXB/slb  
Date: February 20, 2002